Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclopentolate + tropicamide + phenylephrine
- Development stage
- Phase 4
- Lead developer
- Pine Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
This is a fixed-dose combination ophthalmic solution containing three active ingredients—cyclopentolate, tropicamide, and phenylephrine—used primarily for rapid and effective pupillary dilation (mydriasis) during eye examinations or procedures. Cyclopentolate and tropicamide are antimuscarinic agents that block muscarinic acetylcholine receptors in the eye, leading to relaxation of the sphincter muscle of the iris (causing mydriasis) and paralysis of accommodation (cycloplegia). Phenylephrine is an alpha-1 adrenergic receptor agonist that stimulates contraction of the dilator muscle of the iris, further enhancing pupil dilation. The combination provides both strong mydriatic effect and moderate cycloplegic action. It is typically used in clinical settings for diagnostic purposes or preoperative preparation[1][2][6][7].
- Brand names
- TPC Drops
- Other names
- cyclopentolate HCl + tropicamide + phenylephrine HCl ophthalmic solutioncyclopentolate / tropicamide / phenylephrine ophthalmicTPC Drops
02
Targets
ADRA1A (α1A)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)CHRM5 (M5)
Beyond the preview
Go deeper on cyclopentolate + tropicamide + phenylephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclopentolate + tropicamide + phenylephrine.